These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
637 related articles for article (PubMed ID: 8458056)
1. Comparison of empiric aztreonam and aminoglycoside regimens in the treatment of serious gram-negative lower respiratory infections. Bjornson HS; Ramirez-Ronda C; Saavedra S; Rivera-Vázquez CR; Liu C; Hinthorn DR Clin Ther; 1993; 15(1):65-78. PubMed ID: 8458056 [TBL] [Abstract][Full Text] [Related]
2. Combined aztreonam and gentamicin therapy for pseudomonal lower respiratory tract infections. Andrews R; Fasoli R; Scoggins WG; Algozzine GJ; Spann RW; Sundaresh KV; Mathers JA; Babb R; Kuppinger M; Cooper B Clin Ther; 1994; 16(2):236-52. PubMed ID: 8062319 [TBL] [Abstract][Full Text] [Related]
3. Comparison of the efficacy and safety of isepamicin and amikacin in the treatment of acute lower respiratory tract infections caused by gram-negative organisms. Covi M; Velluti G J Chemother; 1995 Jun; 7 Suppl 2():137-42. PubMed ID: 8622102 [TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of isepamicin and ceftazidime compared with amikacin and ceftazidime in acute lower respiratory tract infection. Colardyn F J Chemother; 1995 Jun; 7 Suppl 2():129-35. PubMed ID: 8622101 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Lucasti C; Jasovich A; Umeh O; Jiang J; Kaniga K; Friedland I Clin Ther; 2008 May; 30(5):868-83. PubMed ID: 18555934 [TBL] [Abstract][Full Text] [Related]
7. Overview of the efficacy of isepamicin in the adult core clinical trial programme. Carbon C J Chemother; 1995 Jun; 7 Suppl 2():79-85. PubMed ID: 8622115 [TBL] [Abstract][Full Text] [Related]
8. A comparison of aztreonam plus vancomycin and imipenem plus vancomycin as initial therapy for febrile neutropenic cancer patients. Raad II; Whimbey EE; Rolston KV; Abi-Said D; Hachem RY; Pandya RG; Ghaddar HM; Karl CL; Bodey GP Cancer; 1996 Apr; 77(7):1386-94. PubMed ID: 8608520 [TBL] [Abstract][Full Text] [Related]
9. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study. Deal EN; Micek ST; Reichley RM; Ritchie DJ Clin Ther; 2009 Feb; 31(2):299-310. PubMed ID: 19302902 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of the efficacy and safety of isepamicin compared with amikacin in the treatment of nosocomial pneumonia and septicaemia. Beaucaire G J Chemother; 1995 Jun; 7 Suppl 2():165-73. PubMed ID: 8622107 [TBL] [Abstract][Full Text] [Related]
11. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E; J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704 [TBL] [Abstract][Full Text] [Related]
12. A randomized controlled clinical trial on piperacillin/tazobactam versus ticarcillin/clavulanic acid for the treatment of bacterial infections. Hou F; Li J; Gao L; Chen Y Chin Med J (Engl); 1998 Nov; 111(11):1039-43. PubMed ID: 11189212 [TBL] [Abstract][Full Text] [Related]
13. Cefepime versus ticarcillin and clavulanate potassium and aztreonam for febrile neutropenia therapy in high-dose chemotherapy patients. Fleming DR; Ziegler C; Baize T; Mudd L; Goldsmith GH; Herzig RH Am J Clin Oncol; 2003 Jun; 26(3):285-8. PubMed ID: 12796602 [TBL] [Abstract][Full Text] [Related]
14. Clinical and economic evaluation of subsequent infection following intravenous ciprofloxacin or imipenem therapy in hospitalized patients with severe pneumonia. Caldwell JW; Singh S; Johnson RH J Antimicrob Chemother; 1999 Mar; 43 Suppl A():129-34. PubMed ID: 10225583 [TBL] [Abstract][Full Text] [Related]
15. Use of aztreonam in patients suffering from urinary tract infections with contraindications for the use of aminoglycosides. Fraschini F; Scaglione F; Alessandria M; Gattei G Chemioterapia; 1986 Oct; 5(5):319-21. PubMed ID: 3791478 [TBL] [Abstract][Full Text] [Related]
16. Clindamycin plus amikacin versus clindamycin plus aztreonam in established intraabdominal infections. Barboza E; del Castillo M; Yi A; Gotuzzo E Surgery; 1994 Jul; 116(1):28-35. PubMed ID: 8023265 [TBL] [Abstract][Full Text] [Related]
17. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics. Burgess DS; Frei CR J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664 [TBL] [Abstract][Full Text] [Related]
18. Antibiotic use in neonatal sepsis. Yurdakök M Turk J Pediatr; 1998; 40(1):17-33. PubMed ID: 9722468 [TBL] [Abstract][Full Text] [Related]
19. Role of aztreonam in lower respiratory tract infections. Cook JL Urology; 1988 Jun; 31(6 Suppl):33-6. PubMed ID: 3287748 [TBL] [Abstract][Full Text] [Related]
20. Comparison of the efficacy and safety of isepamicin and amikacin in the treatment of skin and skin structure infections. Rodriguez-Noriega E; Esparza-Ahumada S; Morfin-Otero R J Chemother; 1995 Jun; 7 Suppl 2():155-60. PubMed ID: 8622105 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]